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INTRODUCTION
FcεRI is a high-affinity immunoglobulin E (IgE) receptor I that 
contains four distinct polypeptide chains: an extracellular α- 
chain, a β-chain, and a dimer of γ-chains.1 The extracellular 
binding domain of the α-chain binds with high affinity to the Fc 
region of IgE, whereas the other chains are responsible for the 
transduction of initial cross-linking signals into the cell through 
phosphorylation of their intracytoplasmatic immune-recep-
tor tyrosine-based activation motif.2-4 Elevated serum IgE levels 
upregulate FCεRI, increase the sensitivity of these cells to aller-
gen-triggered activation, and enhance cell survival.5-9 When an 
antigen cross-links with an IgE bound to its FcεRI on these cells, 
an allergic reaction is initiated, resulting in the synthesis and re-
lease of a variety of allergic mediators. A number of these medi-
ators (e.g., histamine, neutral proteases, proteoglycans, proin-
flammatory lipid mediators, and cytokines) are released from 
the mast cells and basophils.7,10,11 These cytokines and media-
tors continuously induce IgE production in immunoglobulin 
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class-switching B cells9 and induction of eosinophil infiltra-
tion as well as airway hyperresponsiveness.12 
Since allergen cross-linking with FcεRI-bound IgE is consid-
ered the initial factor in the allergic cascade, therapeutic ap-
proaches intervening the binding of IgE to its receptor have been 
repeatedly proposed. Antibodies have been developed to pre-
vent IgE from binding to FcεRI, by blocking the ability of IgE to 
induce upregulation. The first approved therapeutic antibody 
was a humanized monoclonal anti-IgE antibody (omalizumab), 
which prevents IgE from binding to receptors in order to sup-
press the allergen-mediated degranulation of mast cells and 
basophils.13-16 Another possible target of a therapeutic antibody 
could be FcεRI. However, a full antibody structure could lead 
to an agonist-like effect; hence, we designed a monoclonal an-
tibody of the Fab fragment to block FcεRIα instead.
In this study, we developed NPB311, a humanized mono-
clonal antibody Fab fragment containing FcεRIα-binding sites 
but lacking the Fc portion, and investigated the affinity of 
NPB311 for recombinant FcεRIα by surface plasmon resonance 
(SPR). We also examined whether NPB311 could inhibit β- 
hexosaminidase, histamine and Ca2+ release in vitro by using 
rat basophilic leukemia (RBL-SX38) cells17 that express hu-
man FcεRIα. From these and additional studies using human 
FcεRIα-transgenic mice, we concluded that NPB311 has the 
ability to regulate the IgE-FcεRIα complex in response to IgE 
in IgE-dependent passive cutaneous anaphylaxis (PCA) mice.
MATERIALS AND METHODS
Phage display against human FcεR1α
Human recombinant FcεR1α-Fc fusion protein (Origene Tech-
nologies, Rockville, MD, USA) was coated on a plate and the 
human scFv phage library was added. After incubation, bound 
phages were detached by 0.1 M triethylamine treatment. Se-
lected phages were added to the FcεR1α-Fc fusion protein-
coated plate, followed by incubation with horseradish peroxi-
dase (HRP)-conjugated anti-M13. Luminescence was measured 
with the LumiGLO chemiluminescence kit (KPL, Gaithers-
burg, MD, USA) according to the manufacturer’s instructions.
The IgE-binding competitive activity of the selected anti-
body was measured by competition enzyme-linked immuno-
sorbent assay (ELISA). A plate was coated with FcεR1-Fc fusion 
protein (0.1 μg/mL), and selected phages were added by pan-
ning. After washing, 0.1 μg/mL of human IgE (hIgE) (Abcam, 
Cambridge, MA, USA) was added, followed by HRP-conjugat-
ed mouse anti-hIgE, and luminescence was detected.
IgG conversion and digestion
From the selected scFv expressed in Escherichia coli, the heavy 
chain and light chain were synthesized by polymerase chain 
reaction and ligated into the human IgG2 constant domain-
expressing vector. The reconstructed DNA was transformed to 
DH5 competent cells. Antibodies were obtained by transient 
transfection in 293E cells and quantified by direct ELISA. Plates 
were coated with either anti-human lambda or kappa antibod-
ies, respectively. Diluted (1:200) conditioned medium from a 
culture of transient transfection cells was added to each well. 
After 1 h incubation, HRP-conjugated anti-hIgG was added 
and luminescence was detected. 
The Fab fragment was prepared by papain digestion of the 
NPB311-IgG complex, using a Fab preparation kit (Pierce, Ther-
mo Scientific, Rockford, IL, USA). Papain digestion was car-
ried out according to the manufacturer’s instructions. Frac-
tions collected during the papain digestion and Fab purification 
were analyzed under reducing conditions by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
Fc part and undigested IgG molecules were removed by affin-
ity purification using a Protein A bead column (GE Healthcare 
Bio-Sciences, Pittsburgh, PA, USA). Size-exclusion chroma-
tography using a Hiprep 26/60 Sephacryl S-200 HR column 
(GE Healthcare Bio-Sciences) in 50 mM Tris and 150 mM 
NaCl (pH 7.0) buffer was used as the final purification step of 
the Fab fragment.
Competition and binding assays
Candidate antibodies were produced by transient transfection 
in 293E cells and purified by protein A column chromatogra-
phy (KPL). The purified proteins were added to a plate coated 
with 0.2 μg/mL FcεR1α protein and incubated for 1 h at 37°C. Af-
ter washing, 0.2 μg/mL hIgE was added and the plate was fur-
ther incubated for 1 h at 37°C. Competition was measured by re-
action with HRP-conjugated mouse anti-hIgE and detected with 
an EnVision Multilabel Reader using the LumiGLO chemilu-
minescence substrate. Direct binding against FcεR1α on the 
cell surface was measured using RBL-SX38 coated on 96-well 
plates. 
Affinity measurement by surface plasmon resonance
NPB311 was immobilized on a sensor chip (CM5; BiaCore, 
Giles, UK) in 10 mM sodium acetate (pH 5.0) to an immobiliza-
tion level of 1000 response units. Coupling was performed us-
ing 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/N-hy-
droxysuccinimide and 1 M ethanolamine (Biacore) according to 
the manufacturer’s instructions. A negative reference cell was 
prepared by the same process but without NPB311. A serial dilu-
tion of NPB311 was made with HBS-EP sample buffer 
(HEPES-buffered saline with EDTA and P20 surfactant; Bi-
acore) (0, 6.25, 12.5, 25, 50, and 100 nM, respectively). Associ-
ation of NPB311 with hIgE were determined by injection of 
NPB311 solution for 4 min at a rate of 30 μL/min, followed by 
injection of buffer solution for 4 min at the same rate. Regener-
ation between each measurement was performed by injection 
of 10 mM glycine (pH 2.0) at 30 μL/min for 40 s, followed by 2 
min of stabilization before the next injection.
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β-hexosaminidase activity assay and histamine 
release measurement 
For determination of NPB311 functional activity, IgE-induced 
β-hexosaminidase and histamine release from cultured RBL-
SX38 cells were measured. Cells were seeded on plates and, af-
ter overnight incubation and washing, either diluted NPB311 
or hIgG was added to the wells, followed by 4-hydroxy-3-ni-
trophenylacetyl (NP)-hIgE (0.5 μg/mL), and the plate was in-
cubated at 37°C for 2 h. Then, 0.1 μg/mL NP-BSA was added 
to each well and the plate was further incubated. Thereafter, 
the supernatants were collected, and residual cells were lysed 
with 0.1% Triton X-100 solution. The production of β-hexo-
saminidase in the medium and in the cell lysates was deter-
mined by a fluorometric assay, using 4-methylumbelliferyl-N-
acetyl-β-D-glucosaminide as the substrate (0.1 mM in 100 mM 
citrate, pH 4.5). After 90 min, the reaction was stopped with 0.2 
M glycine buffer and the plate was read on 380 nm excitation 
and 405 nm emission filters. 
For the histamine release assay, RBL-SX38 cells were plated 
at 2×105 cells/well and incubated with 0.5 mL of medium con-
taining 0.5 μg/mL hIgE, with or without NPB311. After a 12 h 
incubation, the cells were washed with Tyrode’s buffer (125 
mM NaCl, 5 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 5.6 mM 
glucose, 10 mM Hepes/Na+, and 0.1% BSA, pH 7.2) and then 
incubated in 0.5 mL of Tyrode’s buffer containing 0.1 μg/mL 
NP-BSA for 30 min. The supernatants were collected and ana-
lyzed for histamine content, using a HTRF histamine assay kit 
according to the manufacturer’s instruction. 
Measurement of cytosolic Ca2+ concentrations
Cells were seeded at 5×104 cells/well per 100 μL loading me-
dium (RPMI 1640, 10% FBS) into 96-well black wall plates. Af-
ter 24 h, medium was replaced with NPB311 followed by ad-
dition of NP-IgE. After 2 h incubation, antibody/IgE mixture was 
aspirated, leaving the cell monolayer intact, and replaced with 
100 μL/well of FLUO-4AM loading buffer [Dulbecco’s modi-
fied Eagle’s medium with 0.1% FBS, 20 mM HEPES, 2.5 mM 
probenecid and 2 μg/mL FLUO-4AM (Invitrogen, Life Tech-
nologies, Carlsbad, CA, USA)] for 1 h at 37°C. Cells were washed 
with PBS and placed in 100 μL/well of Fluorometric Imaging 
Plate Reader (FLIPR) buffer (125 mM NaCl, 5 nM KCl, 1 mM 
MgCl2, 1.5 mM CaCl2, 30 mM HEPES, 2.5 mM probenecid, 5 
mM glucose, 0.01% v/v fetal calf serum) with FLIPR 4 dye. 
Fluorescence of the FLUO-4AM dye was recorded every 2 sec.
 
Animals
B6.Cg-Fcer1atm1Knt Tg(FCER1A)1Bhk/J mice were purchased 
from Jackson Laboratory (Bar Harbor, ME, USA). C57BL/6 mice 
were purchased from Orient Bio (Seongnam, Korea). Animals 
were kept in a specific pathogen-free facility under alternate 
dark-light cycles of 12 h at room temperature. The care and 
treatment of all animals were done in agreement with the In-
stitutional Animal Care and Use Committee of Yonsei Univer-
sity, Seoul, Korea.
Measurement of preventive effects on anaphylactic 
reactions in mice
Specific pathogen-free female wild-type and B6.Cg-Fcer1atm1Knt 
Tg(FCER1A)1Bhk/J mice were injected subcutaneously with 
0.1 μg of NP-IgE, with or without NPB311. At 30 min or 24 h 
after sensitization, the mice were tail-intravenously challenged 
with 0.1 mL of 1% Evans blue (EB) dye solution containing 1 
mg/mL of NP-BSA. Cutaneous anaphylaxis was assessed visu-
ally by the blue dye leakage from blood vessels into the skin.
Statistical analyses 
Statistical analysis was carried out with Sigma plot 10.0 soft-
ware (Jandel Scientific, Sausalito, CA, USA). All data are ex-
pressed as means±SDs and represent one of four independent 
experiments. Significant differences between two groups were 
estimated using the unpaired Student’s t-test. Statistical sig-
nificance was set at p≤0.05.
RESULTS
Development of an anti-FcεRI Fab fragment antibody 
More than 3500 individual clones were isolated and subse-
quently characterized for their specificity, affinity, and ability 
to block IgE binding to FcεRIα. Biopanning against FcεRIα was 
performed using the human scFv phage display library, on 
which phage with a binding capacity to FcεRIα was enriched. 
The specificity of the polyclonal phage after panning was veri-
fied by ELISA using recombinant FcεRIα in microplates. After 
this panning, the affinities of candidates were increased. Among 
them, the anti-FcεRIα Fab fragment mAb NPB311, which 
showed high reactivity against human FcεRIα in direct ELISA 
and blocking of the IgE-FcεRIα complex in competition ELSIA, 
was selected (Fig. 1).
We also checked the quality and purity of Fab fragment mAb 
NPB311 by SDS-PAGE and HPLC. High performance liquid 
chromatography (HPLC) analysis indicated that the purity of 
NPB311 was >93% (Fig. 2A), and NPB311 had no structural 
changes after incubation at 4°C for the indicated time (Fig. 2B).
 
Effect of NPB311 on [Ca2+] in RBL-SX38 cells
The allergy profile is based on the crosslinking of IgE-antigen 
complexes to high-affinity IgE receptors (FcεRI) on immune 
effector cells, which leads to the release of variety of mediators 
such as a protein tyrosine kinase- and calcium (Ca2+)-depen-
dent signal cascade.18 Therefore, we identified the inhibition 
effect of NPB311 on [Ca2+] release. As shown in Fig. 3A, incu-
bation of RBL-SX38 cells with NP-IgE, followed by the treat-
ment with NPB311, inhibited strong drop of florescence in cells 
dose-dependently. No increase of [Ca2+] florescence was ob-
served by adding 100 nM NPB311 with NP-IgE. Next, we ex-
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amined the NPB311 agonistic activity against hFcεRIα. Cultured 
RBL-SX38 cells were stimulated with NPB311, and then Ca2+ 
fluorescence was examined. At concentrations of 0 and 500 nM, 
NPB311 did not show the agonist-induced increase in the bind-
ing of NPB311 to hFcεRIα (Fig. 3B), showing that NPB311 have 
an inhibition effect on IgE binding against hFcεRIα, but no ago-
nist activity against hFcεRIα.
 
NPB311 binding affinity to FcεRIα and inhibition 
of RBL-SX38 cell degranulation 
For evaluation of antigen binding affinity, SPR analysis was per-
formed. Thus, SPR biosensors were utilized to derive the KD 
values for antibody against the immobilized FcεRIα ligand. 
Affinity measurement of NPB311 for hFcεRIα showed a KD 
value of 4 nM (Fig. 4A). To ascertain the inhibition effects of 
NPB311 on cell degranulation, we treated NP-hIgE-sensitized 
RBL-SX38 cells with NPB311, ranging from 0.001 to 20 μg/mL. 
NPB311 significantly suppressed β-hexosaminidase secretion 
(Fig. 4B) and histamine release (Fig. 4C) in IgE-sensitized 
RBL-SX38 cells.
Effect of NPB311 treatment on passive cutaneous 
anaphylaxis
We assessed in vivo activity of NPB311 in transgenic double-
mutant mice that expressed the human high-affinity Iα, in-
stead of mouse FcεRIα, by performing PCA to test the NPB311 
ability to block IgE-driven FcεRI-mediated mast cell release. 
Thus, we intradermally primed the transgenic mice with NP-
hIgE with or without NPB311, and the intensity of the PCA at 
each site was assessed by the size of the skin turning a blue 
color after 30 min. Fig. 5 shows that the size and color intensity 
of the reaction at the sites of NPB311 injection were lower than 
Fig. 1. Development of an anti-FcεRI Fab fragment antibody NPB311. (A) Human FcεRIα was coated on the plate, followed by incubation with the indi-
cated antibodies. Specific antibody binding was detected by further incubation with hIgE, followed by incubation with horseradish peroxidase (HRP)-
conjugated mouse-anti-hIgE and development with Immune Glo substrate. (B) hFcεRIα-expressing RBL-SX38 cells were seeded in a 96-well plate 
followed by incubation with the indicated antibodies. Specific binding was detected by further incubation with HRP-conjugated anti-hIgG and devel-
opment by Immune Glo substrate. FcεRI, high-affinity IgE receptor I; hIgE, human immunoglobulin E; RBL, rat basophilic leukemia.
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Fig. 3. Effect of NPB311 on [Ca2+] in RBL-SX38 cells. (A) RBL-SX38 cells (5×104/well) were incubated at 37°C for 24 h. NP-IgE were treated with/without 
NPB311 (0, 0.16, 0.8, 4, 20, 100, and 500 nM) and incubated at 37°C for 2 h, then FLIPR calcium 4 dye were added. After incubation for 1 h, NP-BSA was 
added and then FLUO-4AM (relative fluorescence units, RFU) was detected every 2 sec and 160 times. (B) RBL-SX38 cells (5×104/well) were incubat-
ed at 37°C for 24 h. NPB311 (0 and 500 nM) were incubated 37°C for 2 h, then FLIPR calcium 4 dye were added. After incubation, NP-BSA was added 
and then FLUO-4AM was detected every 2 sec and 90 times. Results are presented as mean±SD from four independent experiments. FLIPR, Fluoro-
metric Imaging Plate Reader.
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sites injected with NP-hIgE/hIgG.
DISCUSSION
In this study, we have described the Fab fragment antibody 
NPB311, which is targeted against human FcεRIα. We deter-
mined that NPB311 could disrupt IgE binding to FcεRI through 
FcεRIα engagement, then reducing the release of inflammato-
ry mediators in cells. These results came from the following 
findings: 1) NPB311 did not show the agonist-induced in-
crease in the binding of NPB311 against hFcεRIα; 2) NPB311 
inhibited IgE-induced histamine, β-hexosaminidase and Ca2+ 
release; 3) NPB311 reduced IgE-induced dye leakage in the 
PCA murine model. 
Asthma is the most common chronic disease.19 In Korea, it 
is estimated that 2273290 patients have asthma in 2008, ex-
pending $831 million, with an average per capita cost of $366. 
Many clinical trials have shown that omalizumab reduces ex-
acerbation risk and improves health-related quality of life re-
lated to asthma.20 However, omalizumab, is an expensive 
medication (US $1874 per 4 weeks on average).21 Clearly, new 
treatment options are required to improve the management of 
this common and troublesome condition. Antibodies and re-
combinant proteins have been developed to prevent IgE bind-
ing to FcεRIα and block the production of inflammatory me-
diators. Omalizumab binds to IgE, thereby hindering its binding 
to FcεRI and suppressing allergen-mediated degranulation of 
cells. However, omalizumab showed to increase circulating 
IgE level because of the formation of stable omalizumab/IgE 
immune complexes, and high IgE levels are sustained for several 
months after the cessation of drug treatment.22 Unlike omali-
zumab, however, antibody NPB311 reduces the level of IgE in 
the blood, can disrupt IgE-FcεRI binding through FcεRIα en-
gagement and ultimately reduces the releases of inflammato-
ry mediators in cells. Thus, NPB311 could be a new therapeu-
tic strategy of allergic diseases of airway inflammation such as 
asthma.
Fig. 4. Effect of NPB311 on IgE-mediated degranulation in RBL-SX38 cells. (A) Surface plasmon resonance (SPR) traces of the NPB311 binding to 
FcεRIα. Binding curves for FcεRIα were performed at 0, 6.25, 12.5, 25, 50, and 100 nM. (B and C) NP-hIgE was treated with various concentrations of 
antibodies (NPB311 or omalizumab or hIgG), and then 0.5 μg of NP-BSA was added. Supernatants were analyzed for β-hexosaminidase activity and 
histamine release. Results are given as mean±SD, from three separate experiments. Compared with hIgG, *p<0.05; compared with omalizumab, 
†p<0.05. IgE, immunoglobulin E; hIgE, human IgE; RBL, rat basophilic leukemia; FcεRI, high-affinity IgE receptor I; NP, nitrophenylacetyl.
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Other possible target could be IgE-mediated atopic derma-
titis (AD) and urticarial. AD is a chronic inflammatory cutane-
ous disease in childhood, in which the elevated and persistent 
production of IgE plays an important role.23,24 Such a disorder 
is a possible target of anti-IgE treatment, but thus far there are 
scant data on the effects of omalizumab in AD. Recent studies 
described that anti-IgE therapy in patients with AD found symp-
tomatic improvement with omalizumab.25,26 Ozdemir, et al.27 
showed that all patients receiving omalizumab had decreased 
levels of inflammatory mediators and interleukin-9 compared 
to placebo in their randomized, placebo-controlled clinical tri-
al. In addition, patients on anti-IgE therapy had an improve-
ment in clinical outcomes. In this regards, NPB311 could po-
tentially be used as an alternative in the future, thereby sparing 
the use of high potency topical corticosteroids, oral steroid 
dosing, and systemic therapies. 
Generally, the Fab fragment antibody has issues of a short 
half-life in circulation and lack of biological effector functions. 
Nevertheless, full antibodies do not always show optimal ther-
apeutic effects. For example, inappropriate activation of FcεRI-
expressing cells can lead to inflammatory mediator and cyto-
kine release, a potentially fatal immune reaction caused by 
highly elevated levels of different cytokines.28-30 Thus, we man-
ufactured a Fab fragment structure (NPB311) as a potential so-
lution to overcome the unwanted properties of full-structured 
antibodies. In our findings, NPB311 showed high affinity to 
FcεRIα (KD=4 nM), and hIgE-induced histamine, β-hexosami-
nidase (Fig. 4B and C) and Ca2+ release (Fig. 3A) were de-
creased in vitro. To evaluate the efficacy of NPB311 in vivo, we 
developed an IgE-mediated PCA model in transgenic mice 
expressing human FcεRIα. PCA is one of the most important 
local allergic reaction in vivo models. A local dye extravasation 
was induced by a local injection of dye-antigen mixture.31 The 
dye leakage caused by IgE-mediated PCA in mouse ear was 
suppressed by intradermally administered NPB311 (Fig. 5). 
Moreover, in the process of manufacturing NPB311, we ob-
served that it recognized an epitope within the second domain 
of FcεRIα (data not shown). The binding site of NPB311 showed 
major overlap with FcεRI-binding residues on IgE, and thus it 
disrupted the IgE-FcεRI complex. These results indicated that 
NPB311 may suppress the allergen specific inflammatory re-
sponse by inhibiting IgE-FcεRI interaction, regardless of Fab 
fragment and short half-life (Supplementary Method 1, Sup-
plementary Figs. 1 and 2, only online).
Recently, various Fab fragment antibodies have been devel-
oped and studied in murine airway inflammation models.32,33 
A previous study demonstrated the effects of IL-13 Fab frag-
ment treatment on the allergen-induced asthma mouse:34 in-
haled anti-IL-13 Fab significantly reduces airway inflamma-
tion, hyperresponsiveness, and remodeling. Interestingly, 
anti-IL-13 Fab administrated by the in Expose system induced 
a significant decrease of the peribronchial smooth muscle cell 
layer but not in intravenous administration system. In this re-
gard, the use of these alternative administrations could be a 
way to overcome the limited half-life of the Fab fragment in the 
chronic asthma model and help decrease the administered 
dose. However, because of their reduced size, antibody frag-
ments usually penetrate tissues more rapidly and efficiently 
than full IgG, thus this benefit is counterbalanced by a very 
short serum half-life.35 Therefore, further investigation of alter-
native approaches is needed to increase the serum half-life of 
Fab fragment, the most promising one being the chemical ad-
dition, including conjugation of polyethylene glycol (PEG) 
residues,36 fusion of PEG-mimetic polypeptides and albumin-
binding moieties.
In conclusion, anti-FcεRIα Fab fragment may be a useful 
therapeutic agent for the treatment of IgE-dependent inflam-
mation. To overcome the limitation of its short half-life, the im-
plementation of half-life extension might be needed. Also, 
further studies are needed to investigate the NPB311-mediat-
Fig. 5. Effect of NPB311 on dye leakage in a passive cutaneous anaphylaxis model. Human FcεRIα-expressing transgenic mice received an injection 
of NP-hIgE with/without NPB311 (0.05 mg/kg) intradermally into the ear. After (A and B) NPB311 or (C) IgG injection, mice were intravenously adminis-
trated with 1 mg/mL of NP-BSA in Evans blue dye and then the color intensity was evaluated. Left ear: NP-IgE; Right ear: NP-IgE/NPB311. FcεRI, high-
affinity IgE receptor I; NP, nitrophenylacetyl; hIgE, human IgE; IgE, immunoglobulin E.
30 minA 24 hB lgG controlC
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ed changes of decreased inflammation in the allergic diseases 
murine model.
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